BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wouters A, Pauwels B, Lardon F, Pattyn GG, Lambrechts HA, Baay M, Meijnders P, Vermorken JB. In vitro study on the schedule-dependency of the interaction between pemetrexed, gemcitabine and irradiation in non-small cell lung cancer and head and neck cancer cells. BMC Cancer 2010;10:441. [PMID: 20723210 DOI: 10.1186/1471-2407-10-441] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Price A, Yellowlees A, Keerie C, Russell S, Faivre-finn C, Gilligan D, Snee M, Skailes G, Hatton M, Erridge S, Mohammed N. Radical radiotherapy with or without gemcitabine in patients with early stage medically inoperable non-small cell lung cancer. Lung Cancer 2012;77:532-6. [DOI: 10.1016/j.lungcan.2012.05.089] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
2 Jiang T, Su C, Li X, Zhao C, Zhou F, Ren S, Zhou C, Zhang J. EGFR TKIs plus WBRT Demonstrated No Survival Benefit Other Than That of TKIs Alone in Patients with NSCLC and EGFR Mutation and Brain Metastases. Journal of Thoracic Oncology 2016;11:1718-28. [DOI: 10.1016/j.jtho.2016.05.013] [Cited by in Crossref: 65] [Cited by in F6Publishing: 78] [Article Influence: 10.8] [Reference Citation Analysis]
3 Sudo H, Tsuji AB, Sugyo A, Saga T, Kaneko MK, Kato Y, Higashi T. Therapeutic efficacy evaluation of radioimmunotherapy with 90 Y-labeled anti-podoplanin antibody NZ-12 for mesothelioma. Cancer Sci 2019;110:1653-64. [PMID: 30801908 DOI: 10.1111/cas.13979] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
4 Dorn P, Tièche CC, Peng RW, Froment L, Schmid RA, Marti TM. Schedule-dependent increased efficiency of pemetrexed-ionizing radiation combination therapy elicits a differential DNA damage response in lung cancer cells. Cancer Cell Int 2016;16:66. [PMID: 27594806 DOI: 10.1186/s12935-016-0346-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
5 Papp E, Steib A, Abdelwahab EM, Meggyes-Rapp J, Jakab L, Smuk G, Schlegl E, Moldvay J, Sárosi V, Pongracz JE. Feasibility study of in vitro drug sensitivity assay of advanced non-small cell lung adenocarcinomas. BMJ Open Respir Res 2020;7:e000505. [PMID: 32527872 DOI: 10.1136/bmjresp-2019-000505] [Reference Citation Analysis]
6 Tuomainen K, Hyytiäinen A, Al-Samadi A, Ianevski P, Ianevski A, Potdar S, Turunen L, Saarela J, Kuznetsov S, Wahbi W, Risteli M, Mäkitie A, Monni O, Salo T. High-throughput compound screening identifies navitoclax combined with irradiation as a candidate therapy for HPV-negative head and neck squamous cell carcinoma. Sci Rep 2021;11:14755. [PMID: 34285300 DOI: 10.1038/s41598-021-94259-5] [Reference Citation Analysis]
7 Hamid MB, Serafin AM, Akudugu JM. Selective therapeutic benefit of X-rays and inhibitors of EGFR, PI3K/mTOR, and Bcl-2 in breast, lung, and cervical cancer cells. Eur J Pharmacol 2021;912:174612. [PMID: 34736967 DOI: 10.1016/j.ejphar.2021.174612] [Reference Citation Analysis]
8 Williams KS, Secomb TW, El-Kareh AW. Additive Damage Models for Cellular Pharmacodynamics of Radiation-Chemotherapy Combinations. Bull Math Biol 2018;80:1236-58. [PMID: 28849417 DOI: 10.1007/s11538-017-0316-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
9 Argiris A, Pennella E, Koustenis A, Hossain AM, Obasaju CK. Pemetrexed in head and neck cancer: A systematic review. Oral Oncology 2013;49:492-501. [DOI: 10.1016/j.oraloncology.2013.01.007] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
10 Zhao XY, Nie CL, Liang SF, Yuan Z, Deng HX, Wei YQ. Enhanced gemcitabine-mediated cell killing of human lung adenocarcinoma by vector-based RNA interference against PLK1. Biomed Pharmacother. 2012;66:597-602. [PMID: 23153503 DOI: 10.1016/j.biopha.2012.01.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
11 Marcq E, Audenaerde JRV, Waele J, Jacobs J, Loenhout JV, Cavents G, Pauwels P, Meerbeeck JPV, Smits EL. Building a Bridge between Chemotherapy and Immunotherapy in Malignant Pleural Mesothelioma: Investigating the Effect of Chemotherapy on Immune Checkpoint Expression. Int J Mol Sci 2019;20:E4182. [PMID: 31455014 DOI: 10.3390/ijms20174182] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
12 Oleinick NL, Biswas T, Patel R, Tao M, Patel R, Weeks L, Sharma N, Dowlati A, Gerson SL, Fu P, Zhang J, Machtay M. Radiosensitization of non-small-cell lung cancer cells and xenografts by the interactive effects of pemetrexed and methoxyamine. Radiother Oncol 2016;121:335-41. [PMID: 27838149 DOI: 10.1016/j.radonc.2016.10.007] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]